Offering SPR-BLI Services - Proteins provided for free! Here come GMP Grade Cytokines!Free Sample is available!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Immobilized Biotinylated Human CD79B, His,Avitag (Cat. No. CDB-H82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD79B (Polatuzumab) Humanized Antibody with a linear range of 0.1-2 ng/mL (Routinely tested).
The purity of Cynomolgus CD79B, His Tag (Cat. No. CDB-C52H3) is more than 90% and the molecular weight of this protein is around 20-40 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Polatuzumab vedotin | RO-5541077-000; FCU-2711; DCDS-4501A; RG-7596; RO-5541077 | Approved | Seattle Genetics Inc, Genentech Inc | Polivy | United States | Lymphoma, Large B-Cell, Diffuse | Genentech Inc | 2019-06-10 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
TolDCB29 | Phase 2 Clinical | Umc Utrecht | Arthritis, Rheumatoid | Details | |
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR CD19/79b | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
CD79b-19 CAR T Cells Therapy (Massachusetts General Hospital) | Massachusetts General Hospital | Details | |||
Iladatuzumab vedotin | DCDS-0780A; RO-7032005 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Lymphoma, Non-Hodgkin | Details |
CD79b CAR-T cell therapy (Yake Biotechnology) | Phase 1 Clinical | Zhejiang University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Biphenotypic, Acute | Details | |
PRV-3279 | HDM-3002; MGD-010; PRV-3279; CD32BxCD79B | Phase 2 Clinical | Macrogenics Inc | Drug-Related Side Effects and Adverse Reactions; Lupus Erythematosus, Systemic | Details |
Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy(MD Anderson Cancer Center) | JV-213 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, B-Cell; Lymphoma | Details |
NBT-508 | Phase 1 Clinical | Newbio Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
SHR-A1912 | SHR-A1912 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma | Details |
This web search service is supported by Google Inc.